- Dosage: Artesunate 80mg
- Volume: 10 ml per Vial
- Packaging: 10 ml per Vial*1/tray*1 box*1200/Carton
- Shelf Life: 36 months
Package:
Product Description
Product Overview
Artesunate 80mg Powder for Injection is a sterile, lyophilized formulation of artesunate intended for parenteral administration after reconstitution. Each vial contains 80mg of artesunate as a white to off-white lyophilized cake or powder. Artesunate is a semisynthetic derivative of artemisinin, a naturally occurring compound isolated from the leaves of Artemisia annua L. (sweet wormwood), a plant with a long history of use in traditional herbal medicine.
Artesunate 80mg Powder for Injection: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
Buyers usually settle three things before ordering Artesunate 80mg Powder for Injection: the pharmacopoeial monograph, the pack configuration, and the documents the destination authority will ask for.
- For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Artesunate 80mg Powder for Injection. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.
Ordering Parameters for Artesunate 80mg Powder for Injection
| Product Name | Artesunate Powder for Injection |
| Specification | 80mg per vial |
| Dosage Form | Sterile Lyophilized Powder for Solution for Injection / Infusion |
| Active Ingredient | Artesunate |
| Route of Administration | Intravenous injection / infusion, or intramuscular injection (after reconstitution) |
| Storage | Store below 25°C, protected from light and moisture. Do not freeze. Keep vial in outer carton until use. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Artemether 80mg Injection, Quinine Dihydrochloride Injection 2ml:600mg, Artesunate Suppositories 100mg, Artesunate 20mg + Pyronaridine 60mg Granules, Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg.
Pharmacopoeial Standard, Release Testing & COA
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Every batch of Artesunate 80mg Powder for Injection is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The quality control package for the marketed pack covers:
- Testing for assay of the active substance
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Packing, Labelling Languages & Export Paperwork
- Pack size: 80mg lyophilized powder in amber glass vial with rubber stopper and aluminum flip-off cap; supplied with solvent ampoule (Water for Injections or Sodium Bicarbonate solution) where applicable. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, protected from light and moisture. Do not freeze. Keep vial in outer carton until use..
- Shelf life: 24 months (unopened, dry powder). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Marketing Authorisation & Tender Support
Documents for Artesunate 80mg Powder for Injection are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
The context for Artesunate 80mg Powder for Injection is its place among ACT regimens named in the WHO Model List of Essential Medicines. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.
Artesunate 80mg Powder for Injection: Common Procurement Questions
What pack size is available for Artesunate 80mg Powder for Injection?
This presentation is normally supplied as 80mg lyophilized powder in amber glass vial with rubber stopper and aluminum flip-off cap; supplied with solvent ampoule (Water for Injections or Sodium Bicarbonate solution) where applicable. Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.
What documentation comes with a shipment of Artesunate 80mg Powder for Injection?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months.
Does the batch documentation for Artesunate 80mg Powder for Injection support a registration filing?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Can you support registration in my market?
We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.
What is the difference between artesunate and artemether for injection?
Artesunate is the WHO drug of choice for severe malaria and may be given intravenously or intramuscularly at 2.4 mg/kg. Artemether is an alternative given intramuscularly at 3.2 mg/kg on admission then 1.6 mg/kg daily, and must never be given intravenously.
Products Commonly Ordered with Artesunate 80mg Powder for Injection
- Artemether 80mg Injection — 80mg
- Quinine Dihydrochloride Injection 2ml:600mg — 2mL
- Artesunate Suppositories 100mg — 100mg
- Artesunate 20mg + Pyronaridine 60mg Granules — 20mg
- Chloroquine Phosphate 500mg Tablets — 500mg
- Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — 40mg
Browse the full Malaria & ACTs range; all Injectables; the complete product catalogue.
Request a Quotation for Artesunate 80mg Powder for Injection
For tenders and programme supply, send the line item, pack size, quantity and destination for Artesunate 80mg Powder for Injection 80mg. We return a quotation with lead time, documentation list and sample availability in one response.
Sources & Regulatory Notes
- WHO — Malaria case management: operations manual
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
